Publicaciones en colaboración con investigadores/as de Universitat de Barcelona (38)

2023

  1. Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19

    Infectious Diseases Now, Vol. 53, Núm. 7

2021

  1. Fatty liver index as a predictor for type 2 diabetes in subjects with normoglycemia in a nationwide cohort study

    Scientific Reports, Vol. 11, Núm. 1

2019

  1. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

    The Lancet, Vol. 393, Núm. 10189, pp. 2428-2438

2017

  1. Análisis de costes y de coste/eficacia de las pautas recomendadas por GESIDA/Plan Nacional sobre el Sida en 2016 para el tratamiento antirretroviral inicial en adultos infectados por el VIH

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 35, Núm. 2, pp. 88-99

  2. Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 3, pp. 844-849

2016

  1. Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir

    HIV Medicine, Vol. 17, Núm. 5, pp. 340-349

  2. Modification over time of pulse wave velocity parallel to changes in aortic BP, as well as in 24-h ambulatory brachial BP

    Journal of Human Hypertension, Vol. 30, Núm. 3, pp. 186-190

  3. Prevalencia, diagnóstico, tratamiento y control de la hipertensión arterial en España. Resultados del estudio Di@bet.es

    Revista Espanola de Cardiologia, Vol. 69, Núm. 6, pp. 572-578

2015

  1. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792

  2. Renal denervation as treatment of resistant hypertension

    Medicina Clinica, Vol. 145, Núm. 3, pp. 131-135

  3. Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio

    HIV Medicine, Vol. 16, Núm. 6, pp. 370-374

2014

  1. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: Design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial

    Journal of Hypertension, Vol. 32, Núm. 9, pp. 1888-1897

  2. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: A review of available trial evidence

    Journal of Hypertension, Vol. 32, Núm. 9, pp. 1741-1750

  3. Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-Associated Lipodystrophy Syndrome (HALS). A clinical and molecular study

    PLoS ONE, Vol. 9, Núm. 2

  4. Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 9, pp. 583-597

  5. Night-time heart rate cut-off point definition by resting office tachycardia in untreated hypertensive patients: Data of the Spanish ABPM registry

    Journal of Hypertension, Vol. 32, Núm. 5, pp. 1016-1024

  6. Prevalence of plasma lipid abnormalities and its association with glucose metabolism in Spain: The di@bet.es study

    Clinica e Investigacion en Arteriosclerosis, Vol. 26, Núm. 3, pp. 107-114

  7. Reply: Contribution of the ABP-International study to the definition of night-time tachycardia

    Journal of Hypertension

  8. Resumen ejecutivo del documento de consenso sobre el manejo de la patología renal en pacientes con infección por VIH

    Nefrologia, Vol. 34, Núm. 6, pp. 768-788

  9. Variable patterns of obesity and cardiometabolic phenotypes and their association with lifestyle factors in the Di@bet.es study

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 24, Núm. 9, pp. 947-955